caretrace.iopowered by▸healthparse
SearchCohort Builder
Tools▾
KOL FinderTerritoriesDrug Compare
AI Query
Browse▾
By stateBy specialty
Pricing
SearchCohort BuilderToolsKOL FinderTerritoriesDrug CompareAI QueryBrowseBy stateBy specialtyPricing
PROVIDER PROFILE · NPI 1629185483

Cally ChermakMD

DermatologyEdina, MNI
CROSS-REFERENCE

Related data on other Healthparse brands

ProviderScore
OIG/SAM exclusion screening, sanctions history
© 2026 CareTrace
PricingContactPrivacyTerms
REFERRAL NETWORK

Where Cally Chermak's patients come from & go

Directional shared-patient flow from Medicare claims — who sends patients to this provider (inbound) and where this provider's patients go next (outbound). 1 inbound referrers · 0 outbound destinations.

Receives referrals from
Inbound — who sends patients here
PhysicianPatientsVisits
Mark Wilke
Pathology · Plymouth, MN
62111
Refers patients to
Outbound — where patients go next
No outbound pairs above the suppression threshold.
Source: CMS Physician Shared Patient Patterns (30-day window, Medicare FFS). Direction = a beneficiary seen by the first provider, then the second, within 30 days; a proxy for referral, not a documented referral. Pairs with fewer than 11 shared beneficiaries are suppressed.
PRESCRIBING · PART D · 2024
Total Rx claims
974
Beneficiaries
—
Total drug cost
$306K
Distinct drugs
19
Brand share
15.8%
Top prescribed drugs
Triamcinolone Acetonide114 claims
Clobetasol Propionate111 claims
Ketoconazole109 claims
Metronidazole83 claims
Betamethasone/Propylene Glyc79 claims
QUALITY · MIPS · 2024
Final MIPS score
79.3
Quality
58.1
Cost
87.0
Improvement activities
40.0
Promoting interop.
0.0
Payment adjustment
0.18%
Group
MEDICARE UTILIZATION · PART B · 2024
Total beneficiaries
1,364
Unique beneficiaries
—
Total services
2,406
Distinct HCPCS
19
Medicare payment
$100K
Peer benchmark
Q1
Q2
Q3
Q4
Q5
Total Medicare services vs. 255 Dermatology providers in MN — above median (cohort median 1,668).
INDUSTRY PAYMENTS · OPEN PAYMENTS · 2024
No data available for this provider in 2024.